JP2006511536A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511536A5
JP2006511536A5 JP2004560372A JP2004560372A JP2006511536A5 JP 2006511536 A5 JP2006511536 A5 JP 2006511536A5 JP 2004560372 A JP2004560372 A JP 2004560372A JP 2004560372 A JP2004560372 A JP 2004560372A JP 2006511536 A5 JP2006511536 A5 JP 2006511536A5
Authority
JP
Japan
Prior art keywords
weight
drug
water
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004560372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511536A (ja
Filing date
Publication date
Priority claimed from US10/317,657 external-priority patent/US20040115226A1/en
Application filed filed Critical
Publication of JP2006511536A publication Critical patent/JP2006511536A/ja
Publication of JP2006511536A5 publication Critical patent/JP2006511536A5/ja
Pending legal-status Critical Current

Links

JP2004560372A 2002-12-12 2003-12-09 水貧溶性薬物のバイオアベイラビリティーを改善する自由流動性固形製剤およびその製造方法 Pending JP2006511536A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/317,657 US20040115226A1 (en) 2002-12-12 2002-12-12 Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
PCT/US2003/038979 WO2004054540A2 (en) 2002-12-12 2003-12-09 Solid compositions with improved bio-availability of insoluble or poorly water soluble drugs and a corresponding process for preparing such

Publications (2)

Publication Number Publication Date
JP2006511536A JP2006511536A (ja) 2006-04-06
JP2006511536A5 true JP2006511536A5 (enExample) 2006-09-21

Family

ID=32506185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004560372A Pending JP2006511536A (ja) 2002-12-12 2003-12-09 水貧溶性薬物のバイオアベイラビリティーを改善する自由流動性固形製剤およびその製造方法

Country Status (4)

Country Link
US (3) US20040115226A1 (enExample)
JP (1) JP2006511536A (enExample)
AU (1) AU2003300833A1 (enExample)
WO (1) WO2004054540A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016312A1 (en) 2003-08-13 2005-02-24 Nobex Corporation Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
CA2536283A1 (en) * 2003-08-20 2005-03-03 Ajinomoto Co., Inc. Pharmaceutical preparations having an improved solubility
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
JP2007191396A (ja) * 2005-01-07 2007-08-02 Rohto Pharmaceut Co Ltd 皮膚外用剤
GB0612809D0 (en) * 2006-06-28 2006-08-09 Univ Sunderland Formulation
US20100061969A1 (en) * 2006-11-22 2010-03-11 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
WO2009070978A1 (fr) * 2007-11-22 2009-06-11 Yu He Libération rapide dans la cavité buccale des produits de santé et procédé de préparation associé
EP2111854A1 (en) 2008-04-22 2009-10-28 Lek Pharmaceuticals D.D. Self-microemulsifying systems incorporated into liquid core microcapsules
EP2400840A4 (en) * 2009-02-24 2012-08-01 Madeira Therapeutics LIQUID STATINE FORMULATIONS
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US20110160168A1 (en) 2009-12-31 2011-06-30 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
CN103228266B (zh) 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
EA201791738A1 (ru) 2012-05-09 2018-03-30 Вестерн Юниверсити Оф Хелт Сайенсиз Пролипосомальные композиции тестостерона
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
ES2907284T3 (es) 2013-03-15 2022-04-22 Marius Pharmaceuticals Llc Formulaciones de emulsión
US20140370084A1 (en) * 2013-06-18 2014-12-18 Therapeuticsmd, Inc. Estradiol formulations and therapies
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3127502A1 (en) * 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59148718A (ja) * 1983-02-10 1984-08-25 Fujisawa Pharmaceut Co Ltd ユビデカレノン組成物
US4572915A (en) * 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4900734A (en) * 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
DE69229779T2 (de) * 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
FR2714621B1 (fr) * 1994-01-06 1996-02-23 Centre Nat Rech Scient Procédé de préparation de liposomes sans utilisation de solvant organique.
US5938990A (en) * 1994-07-01 1999-08-17 Roche Vitamins Inc. Encapsulation of oleophilic substances and compositions produced thereby
US5863919A (en) * 1994-07-25 1999-01-26 University Of South Florida Lock and key micelles and monomer building blocks therefor
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
IT1289939B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
US6322810B1 (en) * 1997-07-14 2001-11-27 Hayat Alkan-Onyuksel Materials and methods for making improved micelle compositions
IT1294205B1 (it) * 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
AR018528A1 (es) * 1997-12-12 2001-11-28 Expression Genetics Inc Mezcla polimerica biodegradable de micelas para transferencia genetica
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
EP2127642A3 (en) * 1998-08-13 2010-02-24 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
AU3227000A (en) * 1999-02-10 2000-08-29 Ontogeny, Inc. Methods of inducing insulin positive progenitor cells
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9908309D0 (en) * 1999-04-12 1999-06-02 Phares Pharm Res Nv Lipid aggregate forming compositions and their use
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US6890961B2 (en) * 2002-02-01 2005-05-10 Micelle Products, Inc. Clear micellized formulations of β-carotene and method of treating leukoplakia

Similar Documents

Publication Publication Date Title
JP2006511536A5 (enExample)
EP1980242B1 (en) Liquid compositions as a micro-emulsion pre-concentrate comprising drospirenone moleculary dispersed
JP2006511536A (ja) 水貧溶性薬物のバイオアベイラビリティーを改善する自由流動性固形製剤およびその製造方法
JP4943975B2 (ja) 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法
KR101512404B1 (ko) 디하이드로피리딘 칼슘 채널 길항제를 포함하는 향상된 의약 조성물 및 이의 준비 방법
SK287869B6 (sk) Beta-carboline pharmaceutical compositions
JP2004533999A (ja) 医薬形態のアトルバスタチンカルシウム、その構成物、及びアトルバスタチンカルシウムを含む医薬製剤
EP2648700A1 (en) Pharmaceutical composition comprising dutasteride
WO1999030689A1 (en) Pharmaceutical suspension tablet compositions
JP2008531509A (ja) 医薬品成分の改良された分散性を有する錠剤
KR20070119700A (ko) 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제
EP3154522A1 (en) Agomelatine in solution adsorbates and compositions
KR101617054B1 (ko) 고형내복제제
Lee et al. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine
CN114126590B (zh) 医药制剂及其制造方法
EP1952805B1 (en) Tablet containing hydrogenated phospholipids
EA024365B1 (ru) Фармацевтическая композиция, содержащая тамсулозин, и способ ее получения
JP2023052494A (ja) 抗凝固薬の即時放出医薬製剤及びその調製方法
JP5774308B2 (ja) 水溶性ビノレルビン塩の安定な医薬組成物
JP2864737B2 (ja) 徐放性製剤用基剤並びに徐放性製剤及び該製剤の製造方法
JP4467678B2 (ja) テプレノン含有固形製剤
JP4993274B2 (ja) フェノフィブラート含有製剤組成物の製造方法
JP2004518679A (ja) リポイドビヒクルに分散させたサムパトリラートを含む薬学的組成物
JP2022069437A (ja) 医薬製剤およびその製造方法
JPWO2003072095A1 (ja) ソファルコン含有組成物